Perimeter Medical Imaging AI Reports Impressive Q3 2025 Financial Gains Amid Ongoing FDA Review#Canada#FDA_Approval#Toronto#Perimeter_Medical#Imaging_AI
Perimeter Medical Imaging AI Reports Impressive Q3 2025 Financial Gains Amid Ongoing FDA Review
Perimeter Medical Imaging AI shows significant revenue growth in Q3 2025 while awaiting FDA approval for its next-gen B-Series device. Strong commercial traction highlights a promising future.
third-news.com
November 12, 2025 at 10:05 PM
Perimeter Medical Imaging AI Reports Impressive Q3 2025 Financial Gains Amid Ongoing FDA Review#Canada#FDA_Approval#Toronto#Perimeter_Medical#Imaging_AI
Meduloc Achieves FDA Clearance for Innovative Fracture Fixation Device#USA#FDA_Approval#Philadelphia#Meduloc#Orthopedic_Device
Meduloc Achieves FDA Clearance for Innovative Fracture Fixation Device
Meduloc has received FDA clearance for its advanced intramedullary fracture fixation system, promising improved treatment options for small bone fractures across various age groups.
third-news.com
November 12, 2025 at 2:08 PM
Meduloc Achieves FDA Clearance for Innovative Fracture Fixation Device#USA#FDA_Approval#Philadelphia#Meduloc#Orthopedic_Device
DARZALEX FASPRO® Receives FDA Approval for High-Risk Smoldering Multiple Myeloma Treatment#FDA_Approval#DARZALEX_FASPRO®#smoldering_myeloma
DARZALEX FASPRO® Receives FDA Approval for High-Risk Smoldering Multiple Myeloma Treatment
The FDA's recent approval of DARZALEX FASPRO® marks a significant milestone in treating high-risk smoldering multiple myeloma, enabling earlier intervention.
third-news.com
November 6, 2025 at 10:23 PM
DARZALEX FASPRO® Receives FDA Approval for High-Risk Smoldering Multiple Myeloma Treatment#FDA_Approval#DARZALEX_FASPRO®#smoldering_myeloma
Cumberland Pharmaceuticals Achieves 12% Revenue Growth Year-to-Date, Signal for Investors#United_States#Nashville#FDA_Approval#Cumberland_Pharmaceuticals#Talicia
Cumberland Pharmaceuticals Achieves 12% Revenue Growth Year-to-Date, Signal for Investors
Cumberland Pharmaceuticals Inc. reported a 12% rise in year-to-date revenue, totaling $30.8 million. The company is expanding its portfolio and looking to enhance patient care.
third-news.com
November 4, 2025 at 10:12 PM
Cumberland Pharmaceuticals Achieves 12% Revenue Growth Year-to-Date, Signal for Investors#United_States#Nashville#FDA_Approval#Cumberland_Pharmaceuticals#Talicia
Pulsenmore's FDA Approval Marks a Revolutionary Step in Prenatal Care Technology at Home#USA#FDA_Approval#Ramat_Gan#Pulsenmore#Prenatal_Ultrasound
Pulsenmore's FDA Approval Marks a Revolutionary Step in Prenatal Care Technology at Home
Pulsenmore Ltd. has received FDA De Novo marketing authorization for its home-use prenatal ultrasound, enhancing maternal care accessibility and convenience in the U.S.
third-news.com
November 3, 2025 at 11:14 AM
Pulsenmore's FDA Approval Marks a Revolutionary Step in Prenatal Care Technology at Home#USA#FDA_Approval#Ramat_Gan#Pulsenmore#Prenatal_Ultrasound
Revolutionizing Prenatal Care: FDA Authorizes Home Ultrasound by Pulsenmore#USA#FDA_Approval#Ramat_Gan#Pulsenmore#Prenatal_Ultrasound
Revolutionizing Prenatal Care: FDA Authorizes Home Ultrasound by Pulsenmore
Pulsenmore has received FDA De Novo authorization for its home-use prenatal ultrasound device, enabling expectant mothers to have guided scans in their own homes.
third-news.com
November 3, 2025 at 11:11 AM
Revolutionizing Prenatal Care: FDA Authorizes Home Ultrasound by Pulsenmore#USA#FDA_Approval#Ramat_Gan#Pulsenmore#Prenatal_Ultrasound
Implantica Reports Q3 2025: FDA Approval for RefluxStop® Imminent, Strong Sales Performance Highlighted#FDA_Approval#Liechtenstein#Vaduz#Implantica#RefluxStop
Implantica Reports Q3 2025: FDA Approval for RefluxStop® Imminent, Strong Sales Performance Highlighted
Implantica's Q3 2025 report shows strong advancement for RefluxStop® towards FDA approval with increasing sales and positive feedback.
third-news.com
October 31, 2025 at 7:47 AM
Implantica Reports Q3 2025: FDA Approval for RefluxStop® Imminent, Strong Sales Performance Highlighted#FDA_Approval#Liechtenstein#Vaduz#Implantica#RefluxStop
FDA Approval Paves the Way for Revolutionary Dental Mobility Measurement Technology#United_States#FDA_Approval#Redmond#Perimetrics#InnerView
FDA Approval Paves the Way for Revolutionary Dental Mobility Measurement Technology
Perimetrics has received FDA clearance for InnerView®, the first technology to measure internal dental mobility, a game changer for dental diagnostics.
third-news.com
October 28, 2025 at 4:36 PM
FDA Approval Paves the Way for Revolutionary Dental Mobility Measurement Technology#United_States#FDA_Approval#Redmond#Perimetrics#InnerView
Drug Compendia: Key Strategies for Evidence and Payer Coverage in Healthcare#Canada#FDA_Approval#Toronto#Xtalks#Drug_Compendia
Drug Compendia: Key Strategies for Evidence and Payer Coverage in Healthcare
Join the upcoming free webinar to explore how drug compendia bridge the gap between FDA approvals and payer coverage for off-label uses.
third-news.com
October 23, 2025 at 1:04 PM
Drug Compendia: Key Strategies for Evidence and Payer Coverage in Healthcare#Canada#FDA_Approval#Toronto#Xtalks#Drug_Compendia
Simergent's Archimedes™ Home Dialysis System Receives FDA Clearance#United_States#FDA_Approval#Oklahoma_City#Simergent#Archimedes
Simergent's Archimedes™ Home Dialysis System Receives FDA Clearance
Simergent's Archimedes™ Home Dialysis system has received FDA clearance, paving the way for innovative home treatments for patients with kidney failure.
third-news.com
October 14, 2025 at 1:46 PM
Simergent's Archimedes™ Home Dialysis System Receives FDA Clearance#United_States#FDA_Approval#Oklahoma_City#Simergent#Archimedes
Zeta Surgical's TMS Navigation System Achieves FDA Clearance for Enhanced Precision in Treatment#United_States#FDA_Approval#Boston#Zeta_Surgical#TMS_Navigation
Zeta Surgical's TMS Navigation System Achieves FDA Clearance for Enhanced Precision in Treatment
Zeta Surgical's TMS Navigation System has secured FDA 510(k) clearance, advancing treatment precision for neuropsychiatric disorders.
third-news.com
October 13, 2025 at 12:47 PM
Zeta Surgical's TMS Navigation System Achieves FDA Clearance for Enhanced Precision in Treatment#United_States#FDA_Approval#Boston#Zeta_Surgical#TMS_Navigation
Implantica Achieves Key Milestone in FDA Approval for RefluxStop® Device#FDA_Approval#Liechtenstein#Vaduz#Implantica#RefluxStop
Implantica Achieves Key Milestone in FDA Approval for RefluxStop® Device
Implantica announces the successful completion of the FDA's 100-Day meeting for its RefluxStop® PMA application, marking a significant milestone.
third-news.com
October 13, 2025 at 9:12 AM
Implantica Achieves Key Milestone in FDA Approval for RefluxStop® Device#FDA_Approval#Liechtenstein#Vaduz#Implantica#RefluxStop
Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment#South_Korea#FDA_Approval#Incheon#Celltrion#EYDENZELT
Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment
Celltrion proudly announces the FDA's approval of EYDENZELT®, a biosimilar to EYLEA®, enhancing treatment options for retinal diseases like AMD and DME.
third-news.com
October 9, 2025 at 11:00 PM
Celltrion Secures FDA Approval for EYDENZELT®: A New Hope for Eye Disease Treatment#South_Korea#FDA_Approval#Incheon#Celltrion#EYDENZELT
SQ Innovation's Lasix® ONYU Receives FDA Nod for Heart Failure Edema Treatment#United_States#FDA_Approval#Burlington#Lasix_ONYU#SQ_Innovation
SQ Innovation's Lasix® ONYU Receives FDA Nod for Heart Failure Edema Treatment
SQ Innovation's FDA approval of Lasix® ONYU marks a pivotal advance in treating chronic heart failure-related edema, bringing at-home therapy options to patients.
third-news.com
October 8, 2025 at 12:55 PM
SQ Innovation's Lasix® ONYU Receives FDA Nod for Heart Failure Edema Treatment#United_States#FDA_Approval#Burlington#Lasix_ONYU#SQ_Innovation
AorticLab Achieves Milestone with FDA Approval for FLOWer™ Device Investigation#USA#New_York#FDA_Approval#AorticLab#FLOWer
AorticLab Achieves Milestone with FDA Approval for FLOWer™ Device Investigation
AorticLab has received FDA approval for its FLOWer™ System pivotal clinical investigation, aiming to enhance patient outcomes during cardiac procedures.
third-news.com
October 2, 2025 at 3:38 PM
AorticLab Achieves Milestone with FDA Approval for FLOWer™ Device Investigation#USA#New_York#FDA_Approval#AorticLab#FLOWer
Kedrion Biopharma Celebrates FDA Approval of QIVIGY® for Adults with Primary Immunodeficiency#United_States#FDA_Approval#Fort_Lee#Kedrion_Biopharma#QIVIGY
Kedrion Biopharma Celebrates FDA Approval of QIVIGY® for Adults with Primary Immunodeficiency
Kedrion Biopharma's new IVIG treatment, QIVIGY®, has received FDA approval to aid adults with Primary Humoral Immunodeficiency, marking a significant milestone for the company.
third-news.com
September 29, 2025 at 11:19 AM
Kedrion Biopharma Celebrates FDA Approval of QIVIGY® for Adults with Primary Immunodeficiency#United_States#FDA_Approval#Fort_Lee#Kedrion_Biopharma#QIVIGY
FluidAI Medical's Origin™ Achieves FDA Approval, Advancing Post-Operative Care#Canada#FDA_Approval#Kitchener#FluidAI_Medical#Origin™
FluidAI Medical's Origin™ Achieves FDA Approval, Advancing Post-Operative Care
FluidAI Medical's Origin™ device has gained FDA 510(k) clearance, marking a significant advancement in data-driven postoperative patient monitoring.
third-news.com
September 26, 2025 at 6:36 PM
FluidAI Medical's Origin™ Achieves FDA Approval, Advancing Post-Operative Care#Canada#FDA_Approval#Kitchener#FluidAI_Medical#Origin™
Oobli's Third FDA Approval Marks a Milestone for Sweet Protein Innovation#United_States#FDA_Approval#Oobli#Sweet_Protein#Davis
Oobli's Third FDA Approval Marks a Milestone for Sweet Protein Innovation
Oobli achieves significant recognition with its third FDA 'no questions' letter, promoting its novel sweet protein derived from the oubli fruit. This breakthrough enhances sugar alternatives in groceries.
third-news.com
September 24, 2025 at 5:29 PM
Oobli's Third FDA Approval Marks a Milestone for Sweet Protein Innovation#United_States#FDA_Approval#Oobli#Sweet_Protein#Davis
Fluid AI Medical's Origin™ Device Achieves FDA Clearance for Enhanced Post-Op Monitoring#Canada#FDA_Approval#Kitchener#Fluid_AI_Medical#Origin™
Fluid AI Medical's Origin™ Device Achieves FDA Clearance for Enhanced Post-Op Monitoring
Fluid AI Medical has received FDA 510(k) clearance for its Origin™ system, enhancing real-time postoperative monitoring and promoting proactive patient care.
third-news.com
September 24, 2025 at 1:40 PM
Fluid AI Medical's Origin™ Device Achieves FDA Clearance for Enhanced Post-Op Monitoring#Canada#FDA_Approval#Kitchener#Fluid_AI_Medical#Origin™
Implantica Receives Positive Feedback from FDA on RefluxStop PMA Submission#FDA_Approval#Liechtenstein#Vaduz#Implantica#RefluxStop
Implantica Receives Positive Feedback from FDA on RefluxStop PMA Submission
Implantica AG reports positive feedback from the FDA concerning the PMA submission for their innovative RefluxStop device, aiming to assist millions suffering from acid reflux.
third-news.com
September 24, 2025 at 6:31 AM
Implantica Receives Positive Feedback from FDA on RefluxStop PMA Submission#FDA_Approval#Liechtenstein#Vaduz#Implantica#RefluxStop
Noul Achieves Milestone with FDA Registration for Cervical Cancer Diagnostic System#South_Korea#FDA_Approval#Yongin#Cancer#Noul_Co.
Noul Achieves Milestone with FDA Registration for Cervical Cancer Diagnostic System
Noul Co., Ltd. has secured FDA registration for its cervical cancer diagnostic cartridge, marking a pivotal step in its expansion into the U.S. market.
third-news.com
September 23, 2025 at 2:11 PM
Noul Achieves Milestone with FDA Registration for Cervical Cancer Diagnostic System#South_Korea#FDA_Approval#Yongin#Cancer#Noul_Co.
Elanco's Zenrelia Label Updated: FDA Removes Vaccine Risk Language#USA#Indianapolis#FDA_Approval#Elanco#Zenrelia
Elanco's Zenrelia Label Updated: FDA Removes Vaccine Risk Language
Elanco has announced an important update to the Zenrelia label, following FDA review, which removes the risk of vaccine-induced disease language.
third-news.com
September 23, 2025 at 10:31 AM
Elanco's Zenrelia Label Updated: FDA Removes Vaccine Risk Language#USA#Indianapolis#FDA_Approval#Elanco#Zenrelia
Cionic Neural Sleeve 2 Approved by FDA: A Leap Forward for Mobility Innovations#United_States#FDA_Approval#San_Francisco#Cionic#Neural_Sleeve_2
Cionic Neural Sleeve 2 Approved by FDA: A Leap Forward for Mobility Innovations
Cionic has received FDA approval for the Neural Sleeve 2, a revolutionary wearable tech designed to enhance mobility and reduce spasms in patients with neurological conditions.
third-news.com
September 23, 2025 at 10:13 AM
Cionic Neural Sleeve 2 Approved by FDA: A Leap Forward for Mobility Innovations#United_States#FDA_Approval#San_Francisco#Cionic#Neural_Sleeve_2
FDA Accelerates Approval of FORZINITY, A Breakthrough Therapy for Barth Syndrome#USA#FDA_Approval#Needham#Barth_Syndrome#FORZINITY
FDA Accelerates Approval of FORZINITY, A Breakthrough Therapy for Barth Syndrome
Stealth BioTherapeutics receives FDA accelerated approval for FORZINITY, marking a pivotal advancement in Barth Syndrome treatment options. This promises hope for many families.
third-news.com
September 20, 2025 at 12:12 AM
FDA Accelerates Approval of FORZINITY, A Breakthrough Therapy for Barth Syndrome#USA#FDA_Approval#Needham#Barth_Syndrome#FORZINITY
Medtronic's FDA-Approved Altaviva™ Device Revolutionizes Treatment for Urge Urinary Incontinence#United_States#FDA_Approval#Medtronic#Galway#Altaviva
Medtronic's FDA-Approved Altaviva™ Device Revolutionizes Treatment for Urge Urinary Incontinence
Medtronic's newly FDA-approved Altaviva™ device offers a groundbreaking approach to treating urge urinary incontinence, enhancing patients' lives.
third-news.com
September 19, 2025 at 12:10 PM
Medtronic's FDA-Approved Altaviva™ Device Revolutionizes Treatment for Urge Urinary Incontinence#United_States#FDA_Approval#Medtronic#Galway#Altaviva